

Title (en)
NANOPARTICULATE FORMULATIONS COMPRISING HMG COA REDUCTASE INHIBITOR DERIVATIVES ("STATINS"), NOVEL COMBINATIONS THEREOF AS WELL AS MANUFACTURING OF THESE PHARMACEUTICAL COMPOSITIONS

Title (de)
PHARMAZEUTISCHE NANOPARTIKEL-FORMULIERUNGEN MIT HMG-COA-REDUKTASE-INHIBITOREN ("STATINE"), NEUE KOMBINATIONEN DAVON SOWIE HERSTELLUNG DIESER PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN

Title (fr)
FORMULATIONS NANOPARTICULAIRES COMPRENANT DES DERIVES D'UN INHIBITEUR DE LA HMG COA-REDUCTASE ("STATINES"), NOUVELLES COMBINAISONS ASSOCIEES ET PRODUCTION DE CES COMPOSITIONS PHARMACEUTIQUES

Publication
EP 1531799 A1 20050525 (EN)

Application
EP 03738952 A 20030610

Priority
• US 0316206 W 20030610
• US 38740402 P 20020610

Abstract (en)
[origin: WO03103640A1] The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin including surface stabilizer. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.

IPC 1-7
A61K 9/51; **A61K 9/16**; **A61K 31/366**; **A61K 31/40**; **A61K 31/405**; **A61K 31/44**; **A61K 31/4025**; **A61K 31/4164**; **A61K 31/185**; **A61K 31/216**; **A61P 3/06**; **A61P 9/10**; **A61P 9/08**; **A61P 9/00**; **A61P 43/00**; **A61P 41/00**

IPC 8 full level
A61K 9/06 (2006.01); **A61K 9/10** (2006.01); **A61K 9/107** (2006.01); **A61K 9/14** (2006.01); **A61K 9/19** (2006.01); **A61K 9/20** (2006.01); **A61K 9/48** (2006.01); **A61K 9/72** (2006.01); **A61K 31/045** (2006.01); **A61K 31/185** (2006.01); **A61K 31/216** (2006.01); **A61K 31/22** (2006.01); **A61K 31/221** (2006.01); **A61K 31/34** (2006.01); **A61K 31/366** (2006.01); **A61K 31/381** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/405** (2006.01); **A61K 31/4155** (2006.01); **A61K 31/4164** (2006.01); **A61K 31/44** (2006.01); **A61K 31/455** (2006.01); **A61K 31/575** (2006.01); **A61K 31/661** (2006.01); **A61K 31/662** (2006.01); **A61K 31/717** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61K 47/02** (2006.01); **A61K 47/04** (2006.01); **A61K 47/08** (2006.01); **A61K 47/10** (2006.01); **A61K 47/12** (2006.01); **A61K 47/14** (2006.01); **A61K 47/18** (2006.01); **A61K 47/20** (2006.01); **A61K 47/22** (2006.01); **A61K 47/24** (2006.01); **A61K 47/26** (2006.01); **A61K 47/28** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61K 47/36** (2006.01); **A61K 47/38** (2006.01); **A61K 47/42** (2006.01); **A61K 47/44** (2006.01); **A61P 1/18** (2006.01); **A61P 3/06** (2006.01); **A61P 9/00** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 25/28** (2006.01); **A61P 41/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 9/145 (2013.01); **A61K 9/146** (2013.01); **A61K 31/185** (2013.01); **A61K 31/216** (2013.01); **A61K 31/366** (2013.01); **A61K 31/40** (2013.01); **A61K 31/4025** (2013.01); **A61K 31/405** (2013.01); **A61K 31/4164** (2013.01); **A61K 31/44** (2013.01); **A61K 45/06** (2013.01); **A61P 1/18** (2017.12); **A61P 3/00** (2017.12); **A61P 3/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 25/28** (2017.12); **A61P 41/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)
See references of WO 03103640A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 03103640 A1 20031218; AU 2003245313 A1 20031222; CA 2488499 A1 20031218; CA 2488499 C 20130319; EP 1531799 A1 20050525; JP 2005532352 A 20051027; JP 4831965 B2 20111207

DOCDB simple family (application)
US 0316206 W 20030610; AU 2003245313 A 20030610; CA 2488499 A 20030610; EP 03738952 A 20030610; JP 2004510760 A 20030610